Company intelligence / Profile preview

Endosane Pharmaceuticals

Berlin, Germany

Ownership: Private
Development stage: Other

Overview

Endosane Pharmaceuticals is developing innovative neuropsychiatric treatments by targeting the endocannabinoid system. Their lead program for schizophrenia is in Phase 2B clinical trials, with the aim of offering therapies that address the root causes of psychiatric disorders, potentially with improved side effect profiles compared to current standards. The company is leveraging cannabinoid science and advanced delivery technologies, such as sol-gel, to enhance drug absorption and efficacy[5][6][7].

Therapeutic areas: Psychiatry
Modalities: Cannabinoid-based small moleculeSol-gel formulation
Industry: Biotech

Partnerships

PreveCeutical Medical Inc. (sol-gel delivery technology)[5][6]University of California Irvine (implied by collaboration with Prof. Dr. F. Markus Leweke)[3]

Beyond the preview

Go deeper on Endosane Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endosane Pharmaceuticals.

Explore the full profile